Uzun Kemiklerin Kronik Osteomiyelit Tedavisi- Teori, Kanıt ve Uygulamalar

Luca DEABATE; Leonardo PAGANI; İlker UÇKAY

doi:10.5578/mjima.6117

Uzun Kemiklerin Kronik Osteomiyelit Tedavisi- Teori, Kanıt ve Uygulamalar

PDF

DERLEME

Uzun Kemiklerin Kronik Osteomiyelit Tedavisi- Teori, Kanıt ve Uygulamalar

Mediterr J Infect Microb Antimicrob 2014;3:9-9 DOI: 10.5578/mjima.6117

, ,

PDF

İzin

Öz

Erişkin hastalarda implantsız kronik osteomiyelitlerin tedavisi cerrahi gerektirmektedir. Antimikrobiyal ajanların kemik içine penetrasyonunda farmakokinetik ve farmakodinamik (PK/PD) parametreler hakkında çeşitli veriler mevcut olsa da konu karmaşıktır ve uygulanabilir değildir. PK/PD bazlı tedavinin, sonucu iyileştirip iyileştirmediği hala çözümlenmemiş bir konudur. Ayrıca cerrahiye eşlik eden antibiyotik tedavisinin ideal süresi de bilinmemektedir. İlk 2-4 haftası intravenöz olmak üzere 6-12 haftalık tedaviler gibi geleneksel öneriler artık, başlangıçtan itibaren oral antibiyotik tedavilerin lehine tartışılmaya başlanmıştır. Erişkinlerde acilen optimal başlama zamanı ve gereksiz reçetelemeyi ve antibiyotik direncini ortadan kaldıran süreleri belirleyen randomize çalışmalara ihtiyaç vardır.

Anahtar Kelimeler: Osteomiyelit, antibiyotik tedavisi, süre, penetrasyon, PK/PD

Kaynakça

1

Parsons B, Strauss E. Surgical management of chronic osteomyelitis. Am J Surg 2004; 188: 57-66.

2

Rod-Fleury T, Dunkel N, Assal M, Rohner P, Tahintzi P, Bernard L, Hoffmeyer P, Lew D, Uçkay I. Duration of postsurgical antibiotic therapy for adult chronic osteomyelitis: a single-centre experience. Int Orthop 2011; 35: 1725-31.

3

Haidar R, Der Boghossian A, Atiyeh B. Duration of postsurgical antibiotics in chronic osteomyelitis: empiric or evidence-based? Int J Infect Dis 2010; 14: 752-8.

4

Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis 2005; 9: 127-38.

5

Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev 2009; 3: CD004439.

6

Dellamonica P, Bernard E, Etesse H, Garraffo R, Drugeon HB. Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1989; 8: 1024-30.

7

Rao N, Ziran BH, Lipsky BA. Treating osteomyelitis: antibiotics and surgery. Plast Reconstr Surg 2011; 127: 177-87.

8

Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis 2012; 54: 393-407.

9

Uçkay I, Harbarth S, Peter R, Lew D, Hoffmeyer P, Pittet D. Preventing surgical site infections. Expert Rev Anti Infect Ther 2010; 8: 657-70.

10

Amsden GW, Duran JM. Interpretation of antibacterial susceptibility reports. In vitro versus clinical break-points. Drugs 2001; 61: 163-166.

11

Pagani L, Afshari A, Harbarth S. Year in review 2010. Critical Care-infection. Crit Care 2011; 15: 238-45.

12

Nicolau DP, Kuti JL. Optimizing antibiotic-related outcomes in the critically ill patient. Infect Dis Clin Pract 2005; 13: 158-164.

13

Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care 2007; 13: 598-606.

14

Lodise TP, Butterfield J. Use of pharmacodynamic principles to inform beta-lactam dosing: “S” does not always mean Success. J Hosp Med 2011; 6: 16-23.

15

Adembri C, Novelli A. Pharmacokinetic and pharmacodynamic parameters of antimicrobials. Potential for providing dosing regimens that are less vulnerable to resistance. Clin Pharmacokinet 2009; 48: 517-28.

16

DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimizing dosing strategies of antibacterials utilizing pharmacodynamic principles. Impact on the development of resistance. Drugs 2006; 66: 1-14.

17

Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sörgel F. Penetration of antibacterials into bone. Pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009; 48: 89-124.

18

Pea F. Penetration of antibacterials into bone. What do we really know for optimal prophylaxis and treatment of bone and joint infections? Clin Pharmacokinet 2009: 48: 125-7.

19

Incavo SJ, Ronchetti PJ, Choi JH, Wu H, Kinzig M, Sörgel F. Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues. Antimicrob Agents Chemother 1994; 38: 905-7.

20

Rimmelé T, Boselli E, Breilh D, Djabarouti S, Bel JC, Guyot R, Saux MC, Allaouchiche B. Diffusion of levofloxacin into bone and synovial tissues. J Antimicrob Chemother 2004; 53: 533-5.

21

Breilh D, Boselli E, Bel JC, Chassard D, Saux MC, Allaouchiche B. Diffusion of cefepime into cancellous and cortical bone tissue. J Chemother 2003; 15: 134-8.

22

Joukhadar C, Muller M. Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet 2005; 44: 895-913.

23

Bernard L, Uçkay I, Vuagnat A, Assal M, Stern R, Rohner P, Hoffmeyer P. Two consecutive deep sinus tract cultures predict the pathogen of osteomyelitis. Int J Infect Dis 2009; 14: 390-3.

24

Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364: 369-79.

25

Smilack JD, Flittie WH, Williams TW, Jr. Bone concentrations of antimicrobial agents after parenteral administration. Antimicrob Agents Chemother 1976; 9: 169-71.

26

Martini M, Adjrad A, Boudjemaa A. Tuberculous osteomyelitis. A review of 125 cases. Int Orthop 1986: 10; 201-7.

27

Abgueguen P, Pichard E, Aubry J. Buruli ulcer or Mycobacterium ulcerans infection. Med Mal Infect 2010: 40: 60-9.

28

Landais C, Fenollar F, Constantin A, Cazorla C, Guilyardi C, Lepidi H, Stein A, Rolain JM, Raoult D. Q fever osteoarticular infection: four new cases and a review of the literature. Eur J Clin Microbiol Infect Dis 2007; 26: 341-7.

29

Uçkay I, Bouchuiguir-Wafa K, Ninet B, Emonet S, Assal M, Harbarth S, Schrenzel J. Posttraumatic ankle arthritis due to a novel Nocardia species. Infection 2010; 38: 407-12.

30

Sürücüoğlu S, El S, Ural S, Gazi H, Kurutepe S, Taşkıran P, Yurtsever SG. Evaluation of real-time PCR method for rapid diagnosis of brucellosis with different clinical manifestations. Pol J Microbiol 2009; 58: 15-9.

31

Gentry LO. Antibiotic therapy for osteomyelitis. Infect Dis Clin North Am 1990; 4: 485-99.

32

Eyichukwu GO, Anyaehie UE. Outcome of management of chronic osteomyelitis at National Orthopaedic Hospital, Enugu. Niger J Med 2009; 18: 194-8.

33

Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, Bernard L. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther 2004; 29: 351-7.

34

Boffi-El Amari E, Vuagnat A, Stern R, Assal M, Denormandie P, Hoffmeyer P, Bernard L. High versus standard dose vancomycin for osteomyelitis. Scand J Infect Dis 2004; 36: 712-7.

35

Jugun K, Vaudaux P, Garbino J, Pagani L, Hoffmeyer P, Lew D, Uçkay I. The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections. Int Orthop 2013; 37: 1375-80.

36

Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, Gold HS, Baden LR, Pillai SK. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin- resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006; 44: 595-7.

37

Vaudaux P, Kelley WL, Lew DP. Staphylococcus aureus small colony variants: difficult to diagnose and difficult to treat. Clin Infect Dis 2006; 43: 968-70.

38

Uçkay I, Pittet D, Vaudaux P, Sax H, Lew D, Waldvogel F. Foreign body infections due to Staphylococcus epidermidis. Ann Med 2009; 41: 109-19.

39

Lew DP, Waldvogel FA. Use of quinolones in osteomyelitis and infected orthopaedic prosthesis. Drugs 1999: 58: 85-91.

40

Greenberg RN, Newman MT, Shariaty S, Pectol RW. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob Agent Chemother 2000; 44: 164-6.

41

Czekaj J, Dinh A, Moldovan A, Vaudaux P, Gras G, Hoffmeyer P, Lew D, Bernard L, Uçkay I. Efficacy of a combined oral clindamycin-rifampicin regimen for therapy of staphylococcal osteoarticular infections. Scand J Infect Dis 2011; 43: 962-7.

42

Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agent Chemother 2005; 49: 2260-6.

43

Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agent Chemother 2006; 50: 1599- 602.

44

Bernard L, Stern R, Lew D, Hoffmeyer P. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 2003: 36: 1197.

45

Markowitz N, Quinn EL, Saravolatz LD. Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117: 390-8.

46

Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008: 46: 584-93.

47

Atkins B, Gottlieb T. Fusidic acid in bone and joint infections. Int J Antimicrob Agents 1999; 12: 79-93.

48

Drancourt M, Stein A, Argenson JN, Roiron R, Groulier P, Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997; 39: 235-40.

49

Ferry T, Uçkay I, Vaudaux P, François P, Schrenzel J, Harbarth S, Laurent F, Bernard L, Vandenesch F, Etienne J, Hoffmeyer P, Lew D. Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection. Eur J Clin Microbiol Infect Dis 2010; 29: 171-80.

50

Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999; 12: 35-44.

51

Darley ES, MacGowan AP. Antibiotic treatment of grampositive bone and joint infections. J Antimicrob Chemother 2004; 53: 928-35.

52

Seghrouchni K, van Delden C, Dominguez D, Benkabouche M, Bernard L, Assal M, Hoffmeyer P, Uçkay I. Remission after treatment of osteoarticular infections due to Pseudomonas aeruginosa versus Staphylococcus aureus: a case-controlled study. Int Orthop 2011; 36: 1065-71

53

Ferry T, Sénéchal A, Gagnieu MC, Boibieux A, Laurent F, Perpoint T, Tod M, Chidiac C. Prolonged subcutaneous high dose (1 g bid) of Ertapenem as salvage therapy in patients with difficult-to-treat bone and joint infection. J Infect 2012; 65: 579-82.

54

Kanellakopoulou K, Giamarellos-Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. Drugs 2000; 59: 1223-32.

55

Walenkamp GH, Kleijn LL, de Leeuw M. Osteomyelitis treated with gentamicin-PMMA beads: 100 patients followed for 1-12 years. Acta Orthop Scand 1998; 69: 518-22.

56

Uçkay I, Assal M, Legout L, Rohner P, Stern R, Lew D, Hoffmeyer P, Bernard L. Recurrent osteomyelitis caused by infection with different bacterial strains without obvious source of reinfection. J Clin Microbiol 2006; 44: 1194-6.

57

Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003; 51: 1261-8.

58

Simpson AH, Deakin M, Latham JM. Chronic osteomyelitis. The effect of the extent of surgical resection on infection- free survival. J Bone Joint Surg Br 2001; 83: 403-7.

59

Panda M, Ntungila N, Kalunda M, Hinsenkamp M. Treatment of chronic osteomyelitis using the Papineau technique. Int Orthop 1998: 22: 37-40.

60

Siegel HJ, Patzakis MJ, Holtom PD, Sherman R, Shepherd L. Limb salvage for chronic tibial osteomyelitis: an outcomes study. J Trauma 2000; 48: 484-9.